Business Wire

Aviatrix Announces 10,000th “Aviatrix Certified Engineer” (ACE) Milestone and Introduces New Multi-Cloud Network Operations Certification

16.2.2021 17:00:00 EET | Business Wire | Press release

Share

Aviatrix, the cloud network platform, today announced it has reached yet another significant milestone with its Aviatrix Certified Engineers (ACE) Program, while also launching a new multi-cloud network operations curriculum that builds on the basic cloud networking knowledge required to achieve ACE Multi-Cloud Networking Associate certification. The designation ACE Multi-Cloud Network Operations validates a cloud networking professional’s ability to successfully operate and manage multi-cloud networking and security services that support their organization’s needs. This course also introduces CI/CD and Infrastructure-as-a-Code (IaC) concepts, as more innovative solutions for operating cloud networking and security. Automation tools such as Terraform and the Aviatrix multi-cloud Terraform provider help operations an DevOps teams work closely together to deploy a repeatable and auditable infrastructure, leveraging a single CI/CCD pipeline.

With over 10,000 ACEs representing more than 2,500 companies, in over 110 countries worldwide, the Aviatrix ACE Program is the leading and most recognized multi-cloud networking technical certification. Specifically, this training program has helped cloud networking professionals and their companies close the skills gap, learn basic cloud service provider (CSP) constructs and how to add value by learning best practices for multi-cloud network architectures.

“Cloud networking is important but is also very complex. The Aviatrix ACE Program allows me to better understand the designs and limitations of all major cloud service providers (AWS, Azure, GCP, OCI, etc.,). This valuable education also helps architects and engineers design and build enterprise-class cloud networking solutions that meet enterprise-class security, performance, and compliance requirements. I strongly recommend this program to anyone interested in learning more about Hybrid or Multi-Cloud networking,” exclaimed Walter Lee, Sr. Software Engineer, at a leading global financial services company.

The ACE Program helps prepare an organization’s technical staff to lead and accelerate their transformation to cloud. The program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals. The ACE certification is designed for individuals who understand basic networking concepts and prepares engineers and operations staff with knowledge on (1) native cloud networking constructs in AWS, Azure, Google Cloud, and Oracle Cloud Infrastructure and (2) multi-cloud design patterns and concepts and (3) proficiency to plan and provision multi-cloud network use cases and architecture using the Aviatrix cloud network platform.

“The industry demand for the ACE Program over the past 12 months continues to exceed our expectations,” said Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “With ACE, we provide the required training cloud networking professionals need to fully understand public-cloud networking constructs, service provider capabilities, different multi-cloud architectural design patterns, and how to apply this knowledge to their specific environment. Furthermore, our newly launched multi-cloud network operations course will enable the ACEs to successfully run, operate and efficiently manage their business-critical workloads in the cloud. They will also gain greater visibility, observability, and monitoring capabilities that go well beyond the basic operations and troubleshooting tools they get from their CSPs.”

Join the ACE Community Today!

To learn more about the ACE program, including the schedule for self-paced and instructor-led courses, course curriculum and other details, visit https://aviatrix.com/ace/. Or email us at ace@aviatrix.com to request more information.

About Aviatrix

Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact:
Aviatrix
Dmitry Lipkin
dlipkin@aviatrix.com
408-888-2792

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye